Assessment of Resistance Mechanisms and Clinical Implications in Patients WithEGFRT790M–Positive Lung Cancer and Acquired Resistance to Osimertinib-Reference-Cited by-全球学者库

Assessment of Resistance Mechanisms and Clinical Implications in Patients WithEGFRT790M–Positive Lung Cancer and Acquired Resistance to Osimertinib

Published:2018-11-01 Issue:11 Volume:4 Page:1527
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Oxnard Geoffrey R.¹²,Hu Yuebi¹,Mileham Kathryn F.³,Husain Hatim⁴,Costa Daniel B.⁵,Tracy Philip¹⁶,Feeney Nora⁷,Sholl Lynette M.⁸,Dahlberg Suzanne E.¹,Redig Amanda J.¹²,Kwiatkowski David J.¹²,Rabin Michael S.¹²,Paweletz Cloud P.⁷,Thress Kenneth S.⁹,Jänne Pasi A.¹²⁷

Affiliation:

1. Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts

2. Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts

3. Levine Cancer Institute, Carolinas HealthCare System, Charlotte, North Carolina

4. Moores Cancer Center, University of California San Diego, La Jolla

5. Beth Israel Deaconess Medical Center, Boston, Massachusetts

6. Medical student, Tufts University School of Medicine, Boston, Massachusetts

7. Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts

8. Department of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts

9. Translational Sciences, Oncology IMED Biotech Unit, AstraZeneca, Boston, Massachusetts

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Reference38 articles.

1. AZD9291 in EGFR inhibitor–resistant non–small-cell lung cancer.;Jänne;N Engl J Med,2015

2. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer.;Mok;N Engl J Med,2017

3. Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer.;Oxnard;J Clin Oncol,2015

4. Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer.;Soria;N Engl J Med,2018

5. High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression.;Ou;Lung Cancer,2016

Cited by 496 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Liquid biopsy for the management of NSCLC patients under osimertinib treatment;Critical Reviews in Clinical Laboratory Sciences;2024-02-02

2. EZH2/G9a interact to mediate drug resistance in non-small-cell lung cancer by regulating the SMAD4/ERK/c-Myc signaling axis;Cell Reports;2024-02

3. Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancers;2024-01-17

4. Synergistic Anti-Tumor Efficacy Achieved by Reversing Drug Resistance through the Regulation of the Tumor Immune Microenvironment with IL-12 and Osimertinib Combination Therapy;2024-01-16

5. Sinus metastasis of lung adenocarcinoma: a case report;Frontiers in Medicine;2024-01-11